Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.